Orphan Drugs Market Global Report 2020-30

Region:Global

Author(s):

Product Code:7610

Download Sample Report download
Buy the Full ReportStarting from $4000
Published on

April 2020

Total pages

200

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $4000

About the Report

About the Report

The orphan drugs market consists of sales of orphan drugs and related services that are used to treat rare diseases. An orphan drug is a pharmaceutical drug developed to treat patients suffering from rare diseases and would not make profit if developed commercially.
 
The global orphan drugs market was worth USD 132.61 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 7.86% and reach USD 179.49 billion by 2023.
 
The orphan drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region during the period 2015-2023
 
The orphan drugs market covered in this report are segmented by therapy area into oncology, blood, central nervous system, endocrine, cardiovascular, respiratory, immunomodulatory. They are also segmented by distribution channel into hospital pharmacy, retail pharmacy, and online sales.
 
The rising prevalence of rare diseases is a key factor driving the growth of the orphan drugs market. Any disease that affects a small percentage of the population is a rare disease. Rare disease treatments often require a cold chain, a supply chain regulated by temperature that is not readily accessible in all countries. Orphan diseases or rare diseases occurs rarely among the people (i.e. 7 out of 10,000). However, globally, the prevalence of rare diseases is increasing in recent years. In 2017, there were 7,000 identified rare diseases, including hemophilia, Gaucher disease, Hunter syndrome and many types of rare cancer. Some cases of aplastic anemia, caused by damage to stem cells in the bone marrow that are diagnosed in around 500 to 1,000 individuals in the USA each year, are inherited. Thus, the rising prevalence of rare diseases is driving the growth of the orphan drugs market.
 
Lack of supportive government policies hinders the orphan drugs market. Due to the lack of relevant policies for orphan drug, certain drugs do not receive any special recognition or priorities for approval by regulatory authority. Medgenome Labs Ltd., global research partner in accelerating insights into complex genetic diseases, pointed out that companies manufacturing orphan drugs frequently drop out in foreign markets due to a lack of government funding. For example, orphan medical products (OMPs) in India, due to lack of proper regulations and clear guidelines, do not obtain tax cuts or exemptions from customs duties. Therefore, lack of supportive government policies limits the growth of the orphan drugs market.
 
Approval of biological orphan drugs for multiple indication act as a key trend driving the growth of the orphan drugs market. The biological drugs are used for treating rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world. For Instance, in 2018, in order to launch the company's biological orphan drug development program Cardax, Inc. announced that it has been engaged with biological orphan drug expert Frederick D. Sancilio, Ph.D. For the development of commercial products, the companies are focused on obtaining biological orphan drugs to increase their revenue.
 
In November 2019, Bristol-Myers Squibb, a biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines, acquired Celgene for an undisclosed amount. Through this acquisition, Celgene shareholders received for each share, 1 share of Bristol-Myers Squibb common stock, USD 50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of USD 9.00 in cash if certain future regulatory milestones are achieved. Celgene, a biopharmaceutical company positioned to address the needs of the patients with serious diseases.
 
Major players in the market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Amgen, Biogen, Bayer, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson and AbbVie Inc.

Products

Products

1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory; 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales


Companies

Bristol-Myers Squibb Company; Celgene Corporation; F. Hoffmann-La Roche Ltd; Amgen; Biogen; Bayer; Novartis AG; GlaxoSmithKline plc; Johnson & Johnson; AbbVie Inc; Eli Lilly and Company; Alexion Pharmaceuticals; Shire; Novo Nordisk; AstraZeneca; Eisai; Daiichi Sankyo; Merck; Teva Pharmaceutical Industries; Actelion Pharmaceuticals Ltd.; Aegerion Pharmaceuticals

Table of Contents

Table of Contents

1. Executive Summary

2. Orphan Drugs Market Characteristics

3. Orphan Drugs Market Size And Growth

3.1. Global Orphan Drugs Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Orphan Drugs Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Orphan Drugs Market Segmentation

4.1. Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Oncology

Blood

Central Nervous System

Endocrine

Cardiovascular

Respiratory

Immunomodulatory

4.2. Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Hospital Pharmacy

Retail Pharmacy

Online Sales

5. Orphan Drugs Market Regional And Country Analysis

5.1. Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Orphan Drugs Market

6.1. Asia-Pacific Orphan Drugs Market Overview

6.2. Asia-Pacific Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Orphan Drugs Market

7.1. China Orphan Drugs Market Overview

7.2. China Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Orphan Drugs Market

8.1. India Orphan Drugs Market Overview

8.2. India Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Orphan Drugs Market

9.1. Japan Orphan Drugs Market Overview

9.2. Japan Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Orphan Drugs Market

10.1. Australia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Orphan Drugs Market

11.1. Indonesia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Orphan Drugs Market

12.1. South Korea Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Orphan Drugs Market

13.1. Western Europe Orphan Drugs Market Overview

13.2. Western Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Orphan Drugs Market

14.1. UK Orphan Drugs Market Overview

14.2. UK Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Orphan Drugs Market

15.1. Germany Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Orphan Drugs Market

16.3. France Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Orphan Drugs Market

17.1. Eastern Europe Orphan Drugs Market Overview

17.2. Eastern Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Orphan Drugs Market

18.1. Russia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Orphan Drugs Market

19.1. North America Orphan Drugs Market Overview

19.2. North America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Orphan Drugs Market

20.1. USA Orphan Drugs Market Overview

20.2. USA Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Orphan Drugs Market

21.1. South America Orphan Drugs Market Overview

21.2. South America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Orphan Drugs Market

22.1. Brazil Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Orphan Drugs Market

23.1. Middle East Orphan Drugs Market Overview

23.2. Middle East Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Orphan Drugs Market

24.1. Africa Orphan Drugs Market Overview

24.2. Africa Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Orphan Drugs Market Competitive Landscape And Company Profiles

25.1. Orphan Drugs Market Competitive Landscape

25.2. Orphan Drugs Market Company Profiles

25.2.1. Bristol-Myers Squibb Company

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Celgene Corporation

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. F. Hoffmann-La Roche Ltd

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Amgen

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. Biogen

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Orphan Drugs Market

27. Orphan Drugs Market Trends And Strategies

28. Orphan Drugs Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Asia-Pacific, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: China, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: India, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: Japan, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: Australia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: Indonesia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: South Korea, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: Western Europe, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: UK, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: Germany, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: France, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: Eastern Europe, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Russia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: North America, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: USA, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: South America, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: Brazil, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: Middle East, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: Africa, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Bristol-Myers Squibb Company Financial Performance

Figure 27: Celgene Corporation Financial Performance

Figure 28: F. Hoffmann-La Roche Ltd Financial Performance

Figure 29: Amgen Financial Performance

Figure 30: Biogen Financial Performance


List of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Asia-Pacific, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: China, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: India, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: Japan, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: Australia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: Indonesia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: South Korea, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: Western Europe, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: UK, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: Germany, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: France, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: Eastern Europe, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Russia, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: North America, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: USA, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: South America, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: Brazil, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: Middle East, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: Africa, Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Bristol-Myers Squibb Company Financial Performance

Table 27: Celgene Corporation Financial Performance

Table 28: F. Hoffmann-La Roche Ltd Financial Performance

Table 29: Amgen Financial Performance

Table 30: Biogen Financial Performance

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022